Glycan modified nucleic acids, methods of preparation, and therapeutic uses

Patent metadata

Field	Value
Publication number	US-2024261420-A1
Application number	US-202318363050-A
Country	US
Kind code	A1
Filing date	Aug 1, 2023
Priority date	Apr 23, 2021
Publication date	Aug 8, 2024
Grant date	—

Abstract

The present disclosure relates to glyconucleic acids, such as glycoRNA and glycoDNA described herein. Provided are glycosylated ribonucleic acid (glycoRNA)-related methods and compositions.

First claim

1 - 71 . (canceled)

72 . A pharmaceutical composition comprising:
a) a glyconucleic acid or salt thereof, the glyconucleic acid comprising:
i) a short interfering RNA (siRNA); and
ii) at least one oligosaccharide moiety comprising a hybrid type N-glycan comprising a trimannose core, at least one GlcNAc residue on the terminal end of the a1,3 mannose (Man α1,3) arm of the trimannose core and zero or more mannoses on the α1,6 mannose (Man α1,3) arm of the trimannose core, covalently bound to the siRNA; and
b) a pharmaceutically acceptable carrier.

73 . The pharmaceutical composition of claim 72 , wherein at least one terminal residue of the hybrid type N-glycan, comprises a monosaccharide selected from sialic acid, fucose, GlcNAc, mannose, and galactose.

74 . The pharmaceutical composition of claim 72 , wherein the siRNA is covalently bound to the oligosaccharide moiety via a linker group covalently bound to a terminus of the siRNA.

75 . The pharmaceutical composition of claim 72 , wherein the siRNA is covalently bound to the oligosaccharide moiety via a chemical handle inserted between two nucleotides of the siRNA.

76 . The pharmaceutical composition of claim 72 , wherein the at least one oligosaccharide moiety comprises a fucose linked to a GlcNAc residue in a core or a base region of the hybrid type N-glycan.

77 . The pharmaceutical composition of claim 72 , wherein the at least one oligosaccharide moiety comprises a bi-antennary hybrid type N-glycan comprising a first terminal residue and a second terminal residue.

78 . The pharmaceutical composition of claim 77 , wherein at least one of the first terminal residue and the second terminal residue of the hybrid type N-glycan comprises a monosaccharide selected from sialic acid, fucose, GlcNAc, and galactose.

79 . The pharmaceutical composition of claim 77 , wherein at least one of the first terminal residue and the second terminal residue of the hybrid type N-glycan comprises sialic acid.

80 . The pharmaceutical composition of claim 77 , wherein at least one of the first terminal residue and the second terminal residue of the hybrid type N-glycan comprises GlcNAc.

81 . The pharmaceutical composition of claim 77 , wherein at least one of the first terminal residue and the second terminal residue of the hybrid type N-glycan comprises galactose.

82 . The pharmaceutical composition of claim 72 , wherein the at least one oligosaccharide moiety comprises a tri-antennary hybrid type N-glycan comprising a first terminal residue, a second terminal residue, and a third terminal residue.

83 . The pharmaceutical composition of claim 82 , wherein at least one of the first terminal residue, the second terminal residue and the third terminal residue of the hybrid type N-glycan comprises a monosaccharide selected from sialic acid, fucose, GlcNAc, and galactose.

84 . The pharmaceutical composition of claim 82 , wherein at least one of the first terminal residue, the second terminal residue and the third terminal residue of the hybrid type N-glycan comprises sialic acid.

85 . The pharmaceutical composition of claim 82 , wherein at least one of the first terminal residue, the second terminal residue and the third terminal residue of the hybrid type N-glycan comprises GlcNAc.

86 . The pharmaceutical composition of claim 82 , wherein at least one of the first terminal residue, the second terminal residue and the third terminal residue of the hybrid type N-glycan comprises galactose.

87 . The pharmaceutical composition of claim 82 , wherein the at least one oligosaccharide moiety comprises at least 8 monosaccharides.

88 . The pharmaceutical composition of claim 82 , wherein the at least one oligosaccharide moiety comprises at least 10 monosaccharides.

89 . A method of making the glyconucleic acid or salt thereof of claim 72 , wherein the glyconucleic acid is a compound of Formula (I):

or a salt thereof, wherein:
A is an siRNA;
B is a hybrid type N-glycan; and
L comprises a linker formed by a biorthogonal click chemistry reaction between:
a) a polynucleotide that comprises the A and a first click-chemistry handle, and
b) an oligosaccharide moiety that comprises B and a second click chemistry handle;

the method comprising a first step of reacting: the polynucleotide that comprises A and a first click-chemistry handle, and the oligosaccharide moiety that comprises B and a second click-chemistry handle; wherein the reaction of the first step is carried out under biorthogonal click chemistry conditions.

90 . A pharmaceutical composition comprising a glyconucleic acid or salt thereof made by the method of claim 89 .

91 . A pharmaceutical composition comprising:
a) a glyconucleic acid or salt thereof, the glyconucleic acid comprising:
i) a short interfering RNA (siRNA); and
ii) at least one oligosaccharide moiety comprising a high-mannose type N-glycan comprising four or more mannose residues on a di-GlcNAc oligosaccharide structure, covalently bound to the siRNA; and
b) a pharmaceutically acceptable carrier.

92 . The pharmaceutical composition of claim 91 , wherein the siRNA is covalently bound to the oligosaccharide moiety via a linker group covalently bound to a terminus of the siRNA.

93 . The pharmaceutical composition of claim 91 , wherein the siRNA is covalently bound to the oligosaccharide moiety via a chemical handle inserted between two nucleotides of the siRNA.

94 . The pharmaceutical composition of claim 91 , wherein the at least one oligosaccharide moiety comprises a fucose linked to a GlcNAc residue in a core or a base region of the high-mannose type N-glycan.

95 . The pharmaceutical composition of claim 91 , wherein the at least one oligosaccharide moiety comprises a bi-antennary high-mannose type N-glycan comprising a first terminal residue and a second terminal residue.

96 . The pharmaceutical composition of claim 91 , wherein the at least one oligosaccharide moiety comprises a tri-antennary high-mannose type N-glycan comprising a first terminal residue, a second terminal residue, and a third terminal residue.

97 . The pharmaceutical composition of claim 91 , wherein the at least one oligosaccharide moiety comprises at least 8 monosaccharides.

98 . The pharmaceutical composition of claim 91 , wherein the at least one oligosaccharide moiety comprises at least 10 monosaccharides.

99 . The pharmaceutical composition of claim 91 , wherein the at least one oligosaccharide moiety comprises glycan Man(a1-6)[Man(a1-3)]Man(a1-6)[Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc(b1-(“G-7”).

100 . A method of making the glyconucleic acid or salt thereof of claim 91 , wherein the glyconucleic acid is a compound of Formula (I):

or a salt thereof, wherein:
A is an siRNA;
B is a high-mannose type N-glycan; and
L comprises a linker formed by a biorthogonal click chemistry reaction between:
a) a polynucleotide that comprises the A and a first click-chemistry handle, and
b) an oligosaccharide moiety that comprises B and a second click chemistry handle;

the method c

Assignees

• Ganna Bio Inc
• Childrens Medical Ct Corp
• Beth Israel Deaconess Medical Ct Inc
• Univ Leland Stanford Junior

Inventors

• Flynn Ryan Alexander
• Goodman Brian
• Lawlor Ciaran
• Bisaria Namita
• Cummings Richard D
• Wei Mohui
• Bertozzi Carolyn R

Classifications

• A61K48/0041

  the non-active part being polymeric · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P35/00

  Antineoplastic agents · CPC title